论文部分内容阅读
为探索非注射性尿道给药替代海绵体内注射的可行性和安全度，对２４例阳萎患者采用随机分组、自身前后对照、交叉给药的方法，观察经尿道途径给予前列腺素Ｅ１（ＰＧＥ１）６００μｇ与海绵体内注射ＰＧＥ１１５μｇ的血流动力学作用。结果表明，从血管扩张、血流量增加及临床阴茎勃起程度等方面比较，两种给药方式的差异无统计学意义。提示经尿道给予ＰＧＥ１治疗阳萎疗效确实，安全可靠，其６００μｇ剂量足以产生经海绵体内注射ＰＧＥ１１５μｇ的临床疗效，可在临床推广试用。
In order to explore the feasibility and safety of noninvasive urethral injection to replace intracavernous injection, 24 cases of impotence patients were randomly divided into two groups: control group, crossover administration group and transurethral administration group. PGE1 Hemodynamic effects of 600 μg PGE115 μg injected intracavernosally. The results showed that there was no significant difference in the two administration modes from the aspects of vasodilation, blood flow increase and clinical penile erection. Prompted transurethral PGE1 treatment of impotence effect is safe, reliable, 600μg dose sufficient to produce intracavernosal injection of PGE115μg clinical efficacy, clinical trials in the promotion.